Protalix BioTherapeutics, Inc. (PLX) Stock Analysis & Investment Frameworks
Protalix BioTherapeutics, Inc. (PLX) stock analysis on Invetso. Review Protalix BioTherapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Protalix BioTherapeutics, Inc. Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Protalix BioTherapeutics, Inc. Key Financial Metrics
- Market Cap: $211.10M
- Revenue: $52.74M
- ROE: 31.61%
- ROIC: 23.33%
- Dividend Yield: N/A
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Protalix BioTherapeutics, Inc. Investment Frameworks
Invetso analyzes Protalix BioTherapeutics, Inc. (PLX) across the following frameworks:
- Protalix BioTherapeutics, Inc. 10Y Growth Potential
- Protalix BioTherapeutics, Inc. Scenario Analysis
- Protalix BioTherapeutics, Inc. Risks & Opportunities
- Protalix BioTherapeutics, Inc. Economic Moat
- Protalix BioTherapeutics, Inc. Business Model
- Protalix BioTherapeutics, Inc. Management
- Protalix BioTherapeutics, Inc. SWOT Analysis
- Protalix BioTherapeutics, Inc. Porter's 5 Forces
- Protalix BioTherapeutics, Inc. PESTLE Analysis
- Protalix BioTherapeutics, Inc. ESG Analysis